| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 07/30/2026 | ±2.8% | +6.2% | under-priced |
| 04/29/2026 | ±2.8% | -6.2% | under-priced |
| 10/28/2025 | ±1.7% | +11.8% | under-priced |
| 08/01/2025 | ±2.1% | +2.5% | under-priced |
| 04/29/2025 | ±3.0% | -6.9% | under-priced |
| 10/31/2024 | ±1.8% | -9.2% | under-priced |
| 08/01/2024 | ±2.3% | +1.3% | over-priced |
| 05/02/2024 | ±2.3% | +3.8% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $12.23 | $4.3B | $1.3B |
| Q1 FY2026 | $6.75 | $3.6B | $727M |
| Q4 FY2025 | $7.87 | $3.9B | $845M |
| Q3 FY2025 | $13.62 | $3.8B | $1.5B |
Regeneron Pharmaceuticals Inc (REGN) reports in 71 days, with the next report estimated for 11/23/2026. Across the last 8 reports, options priced an average ±2.3% earnings move while the stock actually moved 6.0% on average — the market has tended to under-price REGN's earnings risk. Fundamentals into the print: EPS down 4.5% year-over-year, revenue up 16.7%. QuantLogix's live 5-factor engine currently reads REGN as a buy at 70/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →